Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.
There is increasing evidence that therapeutic agents for raising HDL would be a useful addition to the current treatment approach for preventing coronary heart disease (CHD), especially considering the fact that therapies for lowering LDLs are not fully adequate for preventing CHD. The recent unraveling of some of the complexities of HDL metabolism has led to the identification of new key proteins involved in HDL metabolism, thus giving new hope and ideas for drug targets. This review focuses on apolipoprotein AI mimetic peptides, which are currently being explored as therapeutic agents for a new treatment strategy known as acute HDL therapy.
Sethi
Amar A
AA
National Institutes of Health, Lipoprotein Metabolism Section, Vascular Medicine Branch, National Heart, Lung and Blood Institute, Bldg 10, Room 7N-115, 10 Center Drive, Bethesda, MD 20892-1508, USA.
Amar
Marcelo
M
Shamburek
Robert D
RD
Remaley
Alan T
AT
D000818:Animals; D016632:Apolipoprotein A-I / Q000737:chemistry*; D001161:Arteriosclerosis / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008956:Models, Chemical; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use*
D016632:Apolipoprotein A-I; D010455:Peptides